Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Treatment Approach Gives Patients With Incurable Lung Cancer More Time Without Disease Progression Compared To Placebo
Results from a Phase III study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida today show that patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib (Tarceva®) as first-line maintenance treatment benefited from a significant (29%) improvement in the time they lived without the disease advancing, compared with those who received placebo1. Patients in the global multicentre SATURN trial, which included patients from the UK, received maintenance treatment with erlotinib if their cancer had not progressed on initial chemotherapy. The data showed a significant improvement in the length of time patients lived without their disease getting worse, and without the need for further chemotherapy. 1 The improvement was seen in both of the main types of NSCLC (squamous cell as well as non-squamous cell) and these results form the basis of a submission for regulatory approval of erlotinib to be used in the first-line maintenance setting. 1 Erlotinib is not currently licensed for first line maintenance treatment in NSCLC lung cancer in the UK.
generic viagra online
FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair
The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma.
News of the day
MAP Pharmaceuticals Phase 3 Trial Of Levadex™ Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX™ orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Endocrinology

Bayer Unveils DIDGET(TM), The First And Only Blood Glucose Meter That Connects With The Nintendo DS(TM) Or DS(TM) Lite

Bayer Diabetes Care in the UK and Ireland today unveils "DIDGET(TM), the first and only blood glucose meter for kids with diabetes that connects directly to Nintendo DS(TM) and Nintendo DS(TM) Lite gaming systems. The DIDGET meter is designed to help kids manage this lifelong condition by rewarding them for building consistent blood glucose testing habits and meeting personalised glucose target ranges. "One of the biggest challenges facing parents of children with diabetes is the constant struggle to instil the habit of regular blood glucose testing that is critical for consistent diabetes management," says John Gregory, Professor in Paediatric Endocrinology, Wales School of Medicine, Cardiff University. "Bayer"s DIDGET meter can help ease the parent/child tension that testing often creates by adding an element of fun and rewards to the routine. Because it is designed with children in mind, Bayer"s DIDGET meter can transform a child"s blood glucose testing experience from something they have to do into something they want to do." Building on 40 years of experience, the company is now transforming how kids engage in their diabetes management by tapping into their existing passion for handheld gaming. Bayer"s DIDGET meter positively reinforces consistent testing habits by awarding points that kids can use to unlock new game levels and customise their gaming experience. "The DIDGET meter is a revolutionary development in healthcare management. Up until now, blood glucose monitors have been created with adults in mind," says Sandra Peterson, Head of Bayer Medical Care. "This product was inspired by a parent of a child with diabetes, to directly address the challenges facing kids with diabetes and their parents. Bayer"s DIDGET meter offers play with purpose to encourage kids to regularly monitor their blood glucose and begin to view regular testing as fun." The DIDGET meter, intended for use by kids aged 5-14, will also connect to Bayer"s DIDGET World (http://www.bayerdidget.co.uk), a new password-protected web community where kids can spend points that they earn from consistent monitoring practices and create their own page. Bayer"s DIDGET World is currently in development and will be available soon. Bayer"s DIDGET meter grows with a child"s ability to manage his/her diabetes, offering two testing levels, Basic and Advanced. Self monitoring blood glucose is an essential tool in the optimal management of childhood and adolescent diabetes. Self monitoring blood glucose should be prescribed at a frequency to optimise each child"s diabetes control because frequency of self monitoring blood glucose correlates with glycaemic control(1). Bayer"s DIDGET meter is based on Bayer"s trusted CONTOUR(R) system and uses the same technology and test strips, providing the same easy accuracy, No Coding(TM) technology, automatic correction for haematocrit and common interfering substances including maltose, 5 second test time, a small (0.6 microL) sample size and automatic detection of control solution. Bayer"s DIDGET meter comes with Knock "Em Downs(TM): World"s Fair which includes a full length adventure game and mini game arcade. Bayer"s DIDGET will be available soon. Visit http://www.bayerdidget.co.uk to find out more and register to be notified when Bayer"s DIDGET meter is available. Nintendo DS and DS Lite gaming systems are sold separately. Bayer Diabetes Care UK is working in partnership with the Juvenile Diabetes Research Foundation (JDRF) in the UK and GBP5 from the sale of every meter will be donated to the JDRF. ÷  Diabetes in the UK An estimated 25,000 children under the age of 18 in the UK have diabetes(2). Type 1 diabetes, also called juvenile diabetes, is usually diagnosed in children and young adults. In persons with type 1 diabetes, the body makes little or no insulin, and therefore people with type 1 diabetes need to take insulin for the rest of their lives (3). Type 2 diabetes is usually diagnosed in adults, although increasingly, children are being diagnosed with this condition. Type 2 is associated with obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. In people with type 2 diabetes, the body doesn"t make enough insulin, or the body is unable to utilise the insulin effectively. There are many therapies available, including insulin, for people with type 2 diabetes(4). All people with type 1 and type 2 diabetes must carefully balance food, medications, and activity level to keep blood glucose levels as close to normal as possible in order to avoid long term complications of diabetes (5). References 1. Rewers M, Pihoker C, Donaghue K et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatric Diabetes 2007: 8: 408-418 2. JDRF UK 3. NHS:÷ Introduction ÷  4. NHS:÷ What is it? 5. NHS: Selfhelp Bayer HealthCare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009